Search

Finasteride

[L6244,L10565] In 1998, it was approved by the FDA to treat male pattern hair loss. … It works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects.

Gemtuzumab ozogamicin

On September 1 2017, gemtuzumab ozogamicin was again approved for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia but with a lower dosing regimen and a different schedule … By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death.

Suramin

Suramin is manufactured by Bayer in Germany as Germanin®.

Vasomera

Certolizumab pegol

[A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819]

Delgocitinib

[A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508] … After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024.

Ziftomenib

[L54601] Ziftomenib works by preventing the protein-protein interaction between menin and KMT2A, a complex essential for maintaining the proliferation and survival of these leukemic cells. … [A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory

Propanoic acid

Sodium propionate is is prepared by neutralizing propionic acid with sodium hydroxide. … It is considered generally recognized as safe (GRAS) food ingredient by FDA, where it acts as an antimicrobial agent for food preservation and flavoring agent.

Loracarbef

Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.

Belzutifan

by Merck in 2019). … [L35995] The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers.